Skip to main content
Top
Published in: Journal of Immune Based Therapies and Vaccines 1/2005

Open Access 01-12-2005 | Review

Psoriatic arthritis: Pathogenesis and novel immunomodulatory approaches to treatment

Authors: Sarah Cassell, Arthur Kavanaugh

Published in: Journal of Immune Based Therapies and Vaccines | Issue 1/2005

Login to get access

Abstract

Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy characterized by the association of arthritis and psoriasis. PsA runs a variable course, from mild synovitis to severe, progressive, erosive arthropathy. The pathogenesis of PsA involves alteration in the components of the immune response, although the exact cause of PsA is unknown. A number of patients with severe peripheral arthritis fail to respond to standard conventional therapy. Advances in biotechnology and in our understanding of the immunopathogenesis of PsA have led to great interest and progress in regards to biologic treatments for PsA. Notable success achieved with recently introduced biologic therapies has paved the way for further research and develpoment of additional therapies that should improve outcomes for affected patients.
Literature
2.
go back to reference Gladman DD: Psoriatic arthritis. Rheum Dis Clin North Am. 1998, 24: 829-44. 10.1016/S0889-857X(05)70044-2.CrossRefPubMed Gladman DD: Psoriatic arthritis. Rheum Dis Clin North Am. 1998, 24: 829-44. 10.1016/S0889-857X(05)70044-2.CrossRefPubMed
3.
go back to reference Lawrence RC, Hochberg MC, Kelsey JL, et al: Estimate of the prevalence of selected arthritis and musculoskeletal diseases in the United States. J Rheumatol. 1989, 16: 427-41.PubMed Lawrence RC, Hochberg MC, Kelsey JL, et al: Estimate of the prevalence of selected arthritis and musculoskeletal diseases in the United States. J Rheumatol. 1989, 16: 427-41.PubMed
4.
go back to reference Gladman DD, Farewell VT, Nadeau C: Clinical indicators of progression in psoriatic arthritis: multivariate relative risk mode. J Rheumatol. 1995, 22: 675-9.PubMed Gladman DD, Farewell VT, Nadeau C: Clinical indicators of progression in psoriatic arthritis: multivariate relative risk mode. J Rheumatol. 1995, 22: 675-9.PubMed
6.
go back to reference Leonard DG, O'Duffy JD, Rogers RS: Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc. 1978, 53: 511-8.PubMed Leonard DG, O'Duffy JD, Rogers RS: Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc. 1978, 53: 511-8.PubMed
7.
go back to reference Elkayam O, Ophir J, Yaron M, Caspi D: Psoriatic arthritis: interrelationships between skin and joint manifestations related to onset, course and distribution. Clin Rheumatol. 2000, 19: 301-5. 10.1007/s100670070005.CrossRefPubMed Elkayam O, Ophir J, Yaron M, Caspi D: Psoriatic arthritis: interrelationships between skin and joint manifestations related to onset, course and distribution. Clin Rheumatol. 2000, 19: 301-5. 10.1007/s100670070005.CrossRefPubMed
8.
go back to reference Gladman DD, Anhorn KAB, Schachter RK, Mervart H: HLA antigens in psoriatic arthritis. J Rheumatol. 1986, 13: 586-92.PubMed Gladman DD, Anhorn KAB, Schachter RK, Mervart H: HLA antigens in psoriatic arthritis. J Rheumatol. 1986, 13: 586-92.PubMed
9.
go back to reference Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK: Psoriatic arthritis – an analysis of 220 patients. Quart J Med. 1987, 62: 127-41.PubMed Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK: Psoriatic arthritis – an analysis of 220 patients. Quart J Med. 1987, 62: 127-41.PubMed
10.
go back to reference Espinoza LR: Psoriatic arthritis: further epidemiologic and genetic consideration. Psoriatic arthritis. Edited by: Gerber LH, Espinoza. 1985, Grune & Stratton, Orlando Florida, 9-32. Espinoza LR: Psoriatic arthritis: further epidemiologic and genetic consideration. Psoriatic arthritis. Edited by: Gerber LH, Espinoza. 1985, Grune & Stratton, Orlando Florida, 9-32.
11.
go back to reference Sakkas LI, Loqueman N, Bird H, Vaughan RW, Welsh KI, Panayi GS: HLA class II and T cell receptor gene polymorphisms in psoriatic arthritis and psoriasis. J Rheumatol. 1990, 17: 1487-90.PubMed Sakkas LI, Loqueman N, Bird H, Vaughan RW, Welsh KI, Panayi GS: HLA class II and T cell receptor gene polymorphisms in psoriatic arthritis and psoriasis. J Rheumatol. 1990, 17: 1487-90.PubMed
12.
go back to reference Eastmon CJ: Psoriatic arthritis. Genetics and HLA antigens. Baillieres Clin Rheumatol. 1994, 8: 263-76.CrossRef Eastmon CJ: Psoriatic arthritis. Genetics and HLA antigens. Baillieres Clin Rheumatol. 1994, 8: 263-76.CrossRef
13.
go back to reference Tomfohrde J, Silverman A, Barnes R, et al: Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science. 1994, 264: 1141-5.CrossRefPubMed Tomfohrde J, Silverman A, Barnes R, et al: Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science. 1994, 264: 1141-5.CrossRefPubMed
14.
go back to reference Matthews D, Fry L, Powels A, et al: Evidence that a locus for familial psoriasis maps to chromosome 4q. Nat Genet. 1996, 13: 231-3. 10.1038/ng1096-231.CrossRef Matthews D, Fry L, Powels A, et al: Evidence that a locus for familial psoriasis maps to chromosome 4q. Nat Genet. 1996, 13: 231-3. 10.1038/ng1096-231.CrossRef
15.
go back to reference Burden A, Javed S, Bailey M, et al: Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p. J Invest Dermatol. 1998, 110: 958-60. 10.1046/j.1523-1747.1998.00213.x.CrossRefPubMed Burden A, Javed S, Bailey M, et al: Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p. J Invest Dermatol. 1998, 110: 958-60. 10.1046/j.1523-1747.1998.00213.x.CrossRefPubMed
16.
go back to reference Veal CD, Clough RL, Barber RC, et al: Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci. J Med Genet. 2001, 38: 7-13. 10.1136/jmg.38.1.7.PubMedCentralCrossRefPubMed Veal CD, Clough RL, Barber RC, et al: Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci. J Med Genet. 2001, 38: 7-13. 10.1136/jmg.38.1.7.PubMedCentralCrossRefPubMed
17.
go back to reference Hohler T, Kruger A, Schneider PM, et al: A TNF-α promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol. 1997, 109: 562-5. 10.1111/1523-1747.ep12337469.CrossRefPubMed Hohler T, Kruger A, Schneider PM, et al: A TNF-α promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol. 1997, 109: 562-5. 10.1111/1523-1747.ep12337469.CrossRefPubMed
18.
go back to reference Balding J, Kane D, Lingstone W, Mynett-Johnson L, Bresnihan B, Smith O, FitzGerald O: Cytokine Gene Polymorphisms: Associations with Psoriatic Arthritis Susceptibility and Severity. Arth & Rheum. 2003, 48: 1408-1413. 10.1002/art.10935.CrossRef Balding J, Kane D, Lingstone W, Mynett-Johnson L, Bresnihan B, Smith O, FitzGerald O: Cytokine Gene Polymorphisms: Associations with Psoriatic Arthritis Susceptibility and Severity. Arth & Rheum. 2003, 48: 1408-1413. 10.1002/art.10935.CrossRef
19.
go back to reference Rahman P, Siannis F, Butt C, Farewell V, Peddle L, Pellet F, Gladman D: Meta-Analysis of TNF-Alpha Polymorphisms in Caucasian Psoriatic Arthritis Populations. Ann Rheum Dis. 2005, 64 (SIII): 325- Rahman P, Siannis F, Butt C, Farewell V, Peddle L, Pellet F, Gladman D: Meta-Analysis of TNF-Alpha Polymorphisms in Caucasian Psoriatic Arthritis Populations. Ann Rheum Dis. 2005, 64 (SIII): 325-
20.
go back to reference Gonzalez S, Martinez-Borra J, Lopez-Vazquez A, et al: MICA rather than MICB, TNFA, or HLA-DRB1 is associated with susceptibility to psoriatic arthritis. J Rheumatol. 2002, 29: 973-8.PubMed Gonzalez S, Martinez-Borra J, Lopez-Vazquez A, et al: MICA rather than MICB, TNFA, or HLA-DRB1 is associated with susceptibility to psoriatic arthritis. J Rheumatol. 2002, 29: 973-8.PubMed
21.
go back to reference Vasey FB: Etiology and pathogenesis of psoriatic arthritis. Psoriatic arthritis. Edited by: Gerber LH, Espinoza. 1985, Grune & Stratton, Orlando Florida, 45-57. Vasey FB: Etiology and pathogenesis of psoriatic arthritis. Psoriatic arthritis. Edited by: Gerber LH, Espinoza. 1985, Grune & Stratton, Orlando Florida, 45-57.
22.
go back to reference Vasey FB, Deitz C, Fenske NA, et al: Possible involvement of group A streptococci in the pathogenesis of psoriatic arthritis. J Rheumatol. 1982, 9: 719-22.PubMed Vasey FB, Deitz C, Fenske NA, et al: Possible involvement of group A streptococci in the pathogenesis of psoriatic arthritis. J Rheumatol. 1982, 9: 719-22.PubMed
23.
go back to reference Njobvu P, McGill P: Psoriatic arthritis and human immunodeficiency virus infection in Zambia. J Rheumatol. 2000, 27: 1699-702.PubMed Njobvu P, McGill P: Psoriatic arthritis and human immunodeficiency virus infection in Zambia. J Rheumatol. 2000, 27: 1699-702.PubMed
24.
go back to reference Taglione EV, Martini ML, Galluzzo P, et al: Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. J Rheumatol. 1999, 26: 370-2.PubMed Taglione EV, Martini ML, Galluzzo P, et al: Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. J Rheumatol. 1999, 26: 370-2.PubMed
25.
go back to reference Panayi G: Immunology of psoriasis and psoriatic arthritis. Baillieres Clin Rheumatol. 1994, 8: 419-27.CrossRefPubMed Panayi G: Immunology of psoriasis and psoriatic arthritis. Baillieres Clin Rheumatol. 1994, 8: 419-27.CrossRefPubMed
27.
go back to reference Costello PJ, Winchester RJ, Curran SA, et al: Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions that appear antigen driven. J Immunol. 2001, 166: 2878-86.CrossRefPubMed Costello PJ, Winchester RJ, Curran SA, et al: Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions that appear antigen driven. J Immunol. 2001, 166: 2878-86.CrossRefPubMed
28.
go back to reference Laloux L, Voisin MC, Allain J, et al: Immunohistological study of enthesis in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis. 2001, 60: 316-21. 10.1136/ard.60.4.316.PubMedCentralCrossRefPubMed Laloux L, Voisin MC, Allain J, et al: Immunohistological study of enthesis in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis. 2001, 60: 316-21. 10.1136/ard.60.4.316.PubMedCentralCrossRefPubMed
29.
go back to reference Tassiulas I, Duncan SR, Centola M, et al: Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol. 1999, 60: 479-91. 10.1016/S0198-8859(99)00034-8.CrossRefPubMed Tassiulas I, Duncan SR, Centola M, et al: Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol. 1999, 60: 479-91. 10.1016/S0198-8859(99)00034-8.CrossRefPubMed
30.
go back to reference Ritchlin C, Haas-Smith SA, Hicks D, et al: Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998, 25: 1544-52.PubMed Ritchlin C, Haas-Smith SA, Hicks D, et al: Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998, 25: 1544-52.PubMed
31.
go back to reference Danning CL, Illei GG, Hitchon C, et al: Macrophage-derived cytokine and nuclear factor kappa B p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum. 2000, 43: 1244-56. 10.1002/1529-0131(200006)43:6<1244::AID-ANR7>3.0.CO;2-2.CrossRefPubMed Danning CL, Illei GG, Hitchon C, et al: Macrophage-derived cytokine and nuclear factor kappa B p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum. 2000, 43: 1244-56. 10.1002/1529-0131(200006)43:6<1244::AID-ANR7>3.0.CO;2-2.CrossRefPubMed
32.
go back to reference Saklatvala J: Tumor necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 1986, 322: 547-9. 10.1038/322547a0.CrossRefPubMed Saklatvala J: Tumor necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 1986, 322: 547-9. 10.1038/322547a0.CrossRefPubMed
33.
go back to reference Bertolini DR, Nedwin GE, Bringman TS, et al: Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature. 1986, 319: 516-8. 10.1038/319516a0.CrossRefPubMed Bertolini DR, Nedwin GE, Bringman TS, et al: Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature. 1986, 319: 516-8. 10.1038/319516a0.CrossRefPubMed
34.
go back to reference Ettehadi P, Greaves MW, Wallach D, et al: Elevated tumor necrosis factor alpha biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994, 96: 146-51.PubMedCentralCrossRefPubMed Ettehadi P, Greaves MW, Wallach D, et al: Elevated tumor necrosis factor alpha biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994, 96: 146-51.PubMedCentralCrossRefPubMed
35.
go back to reference Fearon U, Reece R, Smith J, et al: Synovial cytokine and growth factor regulation of MMPs/TIMPs: implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. Ann N Y Acad Sci. 1999, 878: 619-21.CrossRefPubMed Fearon U, Reece R, Smith J, et al: Synovial cytokine and growth factor regulation of MMPs/TIMPs: implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. Ann N Y Acad Sci. 1999, 878: 619-21.CrossRefPubMed
36.
go back to reference Pitzalis C, Cauli A, Pipitone N, et al: Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis. Arthritis Rheum. 1996, 39: 137-45.CrossRefPubMed Pitzalis C, Cauli A, Pipitone N, et al: Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis. Arthritis Rheum. 1996, 39: 137-45.CrossRefPubMed
37.
go back to reference McHugh NJ, Balachrishnan C, Jones SM: Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology. 2003, 42: 778-83. 10.1093/rheumatology/keg217.CrossRefPubMed McHugh NJ, Balachrishnan C, Jones SM: Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology. 2003, 42: 778-83. 10.1093/rheumatology/keg217.CrossRefPubMed
38.
go back to reference Resnick D, Niwayama G: Psoriatic arthritis. Diagnosis of bone joint disorders. 1981, WB Saunder Co, Philadelphia, 1103-29. Resnick D, Niwayama G: Psoriatic arthritis. Diagnosis of bone joint disorders. 1981, WB Saunder Co, Philadelphia, 1103-29.
39.
go back to reference Gladman DD, Shuckett R, Russell ML, et al: Psoriatic arthritis – an analysis of 220 patients. Quart J Med. 1987, 62: 127-41.PubMed Gladman DD, Shuckett R, Russell ML, et al: Psoriatic arthritis – an analysis of 220 patients. Quart J Med. 1987, 62: 127-41.PubMed
40.
go back to reference Jones SM, Armas JB, Cohen MG, et al: Psoriatic arthritis: Outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol. 1994, 33: 834-9.CrossRefPubMed Jones SM, Armas JB, Cohen MG, et al: Psoriatic arthritis: Outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol. 1994, 33: 834-9.CrossRefPubMed
41.
go back to reference Kane D, Stafford L, Bresnihan B, Fitzgerald O: A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology. 2003 Oct 1, Kane D, Stafford L, Bresnihan B, Fitzgerald O: A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology. 2003 Oct 1,
42.
go back to reference Pringle F: A multidisciplinary approach to psoriatic arthropathy. Community Nurse. 1999, 5: 21-2.PubMed Pringle F: A multidisciplinary approach to psoriatic arthropathy. Community Nurse. 1999, 5: 21-2.PubMed
43.
go back to reference Gladman DD, Farewell VT, Wong K, Husted J: Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum. 1998, 41: 1103-10. 10.1002/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N.CrossRefPubMed Gladman DD, Farewell VT, Wong K, Husted J: Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum. 1998, 41: 1103-10. 10.1002/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N.CrossRefPubMed
44.
go back to reference Christophers E, Mrowietz U: Psoriasis. Fitzpatrick's Dermatology in General Medicine. Edited by: Freedberg IM, Eisen AZ, Wolff K. 1999, McGraw Hill, New York, 495-521. 5 Christophers E, Mrowietz U: Psoriasis. Fitzpatrick's Dermatology in General Medicine. Edited by: Freedberg IM, Eisen AZ, Wolff K. 1999, McGraw Hill, New York, 495-521. 5
45.
go back to reference Black RL, O'Brian WM, Van Scott EJ, et al: Methotrexate therapy in psoriatic arthritis: double-blind study on 21 patients. JAMA. 1964, 189: 141-5.CrossRef Black RL, O'Brian WM, Van Scott EJ, et al: Methotrexate therapy in psoriatic arthritis: double-blind study on 21 patients. JAMA. 1964, 189: 141-5.CrossRef
46.
go back to reference Willkens RF, Williams HJ, Ward JR, et al: Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984, 27: 376-81.CrossRefPubMed Willkens RF, Williams HJ, Ward JR, et al: Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984, 27: 376-81.CrossRefPubMed
47.
go back to reference Marquerie L, Flipo RM, Grardel B, et al: Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis. Joint bone spine. 2002, 69: 275-81. 10.1016/S1297-319X(02)00396-2.CrossRef Marquerie L, Flipo RM, Grardel B, et al: Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis. Joint bone spine. 2002, 69: 275-81. 10.1016/S1297-319X(02)00396-2.CrossRef
48.
go back to reference Spadaro A, Taccari E, Mohtadi B, et al: Life-table analysis of cyclosporin A treatment in psoriatic arthritis: comparison with other disease-modifying antirheumatic drugs. Clin Exp Rheumatol. 1997, 15: 609-14.PubMed Spadaro A, Taccari E, Mohtadi B, et al: Life-table analysis of cyclosporin A treatment in psoriatic arthritis: comparison with other disease-modifying antirheumatic drugs. Clin Exp Rheumatol. 1997, 15: 609-14.PubMed
49.
go back to reference Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, Wollenhaupt J, Falk F, Mease P, for the Treatment of Psoriatic Arthritis Study Group: Efficacy and Safety of Leflunomide in the Treatment of Psoriatic Arthritis and Psoriasis: A Multinational, Double Blind, Randomized, Placebo Controlled Clinical Trial. Arthritis Rheum. 2004, 50: 1939-50. 10.1002/art.20253.CrossRefPubMed Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, Wollenhaupt J, Falk F, Mease P, for the Treatment of Psoriatic Arthritis Study Group: Efficacy and Safety of Leflunomide in the Treatment of Psoriatic Arthritis and Psoriasis: A Multinational, Double Blind, Randomized, Placebo Controlled Clinical Trial. Arthritis Rheum. 2004, 50: 1939-50. 10.1002/art.20253.CrossRefPubMed
50.
go back to reference Clegg DO, Reda DJ, Mejias E, et al: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996, 39: 2013-20.CrossRefPubMed Clegg DO, Reda DJ, Mejias E, et al: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996, 39: 2013-20.CrossRefPubMed
51.
go back to reference Ellis CN, Fradin MS, Messana JM, et al: Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. N Engl J Med. 1991, 324: 277-84.CrossRefPubMed Ellis CN, Fradin MS, Messana JM, et al: Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. N Engl J Med. 1991, 324: 277-84.CrossRefPubMed
52.
go back to reference Braun J, Sieper J: Role of novel biological therapies in psoriatic arthritis. Biodrugs. 2003, 17: 187-99.CrossRefPubMed Braun J, Sieper J: Role of novel biological therapies in psoriatic arthritis. Biodrugs. 2003, 17: 187-99.CrossRefPubMed
53.
go back to reference Kavanaugh A, Cohen S, Cush J: The evolving use of TNF inhibitors in rheumatoid arthritis. J Rheumatol. 2004, 31: 1881-4.PubMed Kavanaugh A, Cohen S, Cush J: The evolving use of TNF inhibitors in rheumatoid arthritis. J Rheumatol. 2004, 31: 1881-4.PubMed
54.
go back to reference Moreland LW, Cohen SB, Baumgartner SW, et al: Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol. 2001, 28: 1238-44.PubMed Moreland LW, Cohen SB, Baumgartner SW, et al: Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol. 2001, 28: 1238-44.PubMed
55.
go back to reference Bondeson J, Maini RN: Tumor necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE). Int J Clin Pract. 2001, 55: 211-16.PubMed Bondeson J, Maini RN: Tumor necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE). Int J Clin Pract. 2001, 55: 211-16.PubMed
56.
go back to reference Mease P, Goffe BS, Metz J, et al: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet. 2000, 356: 385-90. 10.1016/S0140-6736(00)02530-7.CrossRefPubMed Mease P, Goffe BS, Metz J, et al: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet. 2000, 356: 385-90. 10.1016/S0140-6736(00)02530-7.CrossRefPubMed
57.
go back to reference Mease P, Kivitz A, Burch F, et al: Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel): results of a phase 3 multicenter clinical trial (abstract). Arthritis Rheum. 2001, 44 (suppl 9): S90- Mease P, Kivitz A, Burch F, et al: Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel): results of a phase 3 multicenter clinical trial (abstract). Arthritis Rheum. 2001, 44 (suppl 9): S90-
58.
go back to reference Clegg DO, Reda DJ, Mejias E, et al: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. Arthritis Rheum. 1996, 39: 2013-20.CrossRefPubMed Clegg DO, Reda DJ, Mejias E, et al: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. Arthritis Rheum. 1996, 39: 2013-20.CrossRefPubMed
59.
go back to reference Felson DT, Andersen JJ, Boers M, et al: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995, 38: 727-35.CrossRefPubMed Felson DT, Andersen JJ, Boers M, et al: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995, 38: 727-35.CrossRefPubMed
60.
go back to reference Mease PJ, Goffe BS, Metz J, et al: Enbrel (etanercept) in patients with psoriatic arthritis and psoriasis (poster). Ann Rheum Dis. 2001, 60 (Suppl 1): 146- Mease PJ, Goffe BS, Metz J, et al: Enbrel (etanercept) in patients with psoriatic arthritis and psoriasis (poster). Ann Rheum Dis. 2001, 60 (Suppl 1): 146-
61.
go back to reference Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W: Etanercept Treatment of Psoriatic Arthritis: Safety, Efficacy, and Effect on Disease Progression. Arthritis Rheum. 2004, 50: 2264-72. 10.1002/art.20335.CrossRefPubMed Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W: Etanercept Treatment of Psoriatic Arthritis: Safety, Efficacy, and Effect on Disease Progression. Arthritis Rheum. 2004, 50: 2264-72. 10.1002/art.20335.CrossRefPubMed
62.
go back to reference Salvarani C, Cantini F, Olivieri I, et al: Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum. 2003, 49: 541-5. 10.1002/art.11201.CrossRefPubMed Salvarani C, Cantini F, Olivieri I, et al: Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum. 2003, 49: 541-5. 10.1002/art.11201.CrossRefPubMed
63.
go back to reference Ogilvie AL, Antoni C, Dechant C, et al: Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol. 2001, 144: 587-9. 10.1046/j.1365-2133.2001.04089.x.CrossRefPubMed Ogilvie AL, Antoni C, Dechant C, et al: Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol. 2001, 144: 587-9. 10.1046/j.1365-2133.2001.04089.x.CrossRefPubMed
64.
go back to reference Van den Bosch F, Kruithof E, Baeten D, et al: Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis. 2000, 59: 428-33. 10.1136/ard.59.6.428.PubMedCentralCrossRefPubMed Van den Bosch F, Kruithof E, Baeten D, et al: Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis. 2000, 59: 428-33. 10.1136/ard.59.6.428.PubMedCentralCrossRefPubMed
65.
go back to reference Antoni C, Kavanaugh A, Kirkham B, et al: The one-year results of the infliximab multinational psoriatic arthritis controlled trial. Arthritis Rheum. 2003, ACR abstract S604 Antoni C, Kavanaugh A, Kirkham B, et al: The one-year results of the infliximab multinational psoriatic arthritis controlled trial. Arthritis Rheum. 2003, ACR abstract S604
66.
go back to reference Van den Bosch F, Kruithof E, Baeten D, et al: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum. 2002, 46: 755-65. 10.1002/art.511.CrossRefPubMed Van den Bosch F, Kruithof E, Baeten D, et al: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum. 2002, 46: 755-65. 10.1002/art.511.CrossRefPubMed
67.
go back to reference Antoni , Krueger , De Vlam, Birbara , Beutler , Guzzo , Zhou , Dooley , Kavanaugh : Infliximab Improves Signs and Symptoms of Psoriatic Arthritis: Results of the IMPACT 2 Trial. Ann Rheum Dis. 2005, 000: 1-8. Antoni , Krueger , De Vlam, Birbara , Beutler , Guzzo , Zhou , Dooley , Kavanaugh : Infliximab Improves Signs and Symptoms of Psoriatic Arthritis: Results of the IMPACT 2 Trial. Ann Rheum Dis. 2005, 000: 1-8.
68.
go back to reference van der Heijde D, Kavanaugh A, Beutler A, Guzzo C, Zhou B, Dooley L, Antoni CE, Krueger GG, Gladman D: Infliximab Inhibits Progression of Radiographic Damage in Patients With Active Psoriatic Arthritis: Results for Impact 2 Trial. Ann Rheum Dis. 2005, 64 (SIII): 109- van der Heijde D, Kavanaugh A, Beutler A, Guzzo C, Zhou B, Dooley L, Antoni CE, Krueger GG, Gladman D: Infliximab Inhibits Progression of Radiographic Damage in Patients With Active Psoriatic Arthritis: Results for Impact 2 Trial. Ann Rheum Dis. 2005, 64 (SIII): 109-
69.
go back to reference Antoni CE, Kavanaugh A, Gladman D, Wassenberg S, Zhou B, Beutler A, Bermester G, Furst DE, Weisman M, Ebner W, Kalden JR, Smolen J, van der Heijde D: Ann Rheum Dis. 2005, 64 (SIII): 107- Antoni CE, Kavanaugh A, Gladman D, Wassenberg S, Zhou B, Beutler A, Bermester G, Furst DE, Weisman M, Ebner W, Kalden JR, Smolen J, van der Heijde D: Ann Rheum Dis. 2005, 64 (SIII): 107-
70.
go back to reference Mease P, Gladman D, Ritchlin C, Ruderman E, Steinfeld S, Choy E, Perdok R, Weinberg M: Adalimumab Therapy in Patients with Psoriatic Arthritis: 24-week Results of a Phase III Study. Arthritis Rheum. 2004, 4097-50 Mease P, Gladman D, Ritchlin C, Ruderman E, Steinfeld S, Choy E, Perdok R, Weinberg M: Adalimumab Therapy in Patients with Psoriatic Arthritis: 24-week Results of a Phase III Study. Arthritis Rheum. 2004, 4097-50
71.
go back to reference Mease PJ, Sharp JI, Ory P, Gladman DD, Ritchlin CT, Choy EH, Weinberg EH: Adalimumab Treatment Effects on Radiographic Progression of Joint Disease in Patients with Psoriatic Arthritis: Result from ADEPT. Ann Rheum Dis. 2005, 64 (SIII): 320- Mease PJ, Sharp JI, Ory P, Gladman DD, Ritchlin CT, Choy EH, Weinberg EH: Adalimumab Treatment Effects on Radiographic Progression of Joint Disease in Patients with Psoriatic Arthritis: Result from ADEPT. Ann Rheum Dis. 2005, 64 (SIII): 320-
72.
go back to reference Weinberg JM: An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther. 2003, 25: 2487-505. 10.1016/S0149-2918(03)80313-2.CrossRefPubMed Weinberg JM: An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther. 2003, 25: 2487-505. 10.1016/S0149-2918(03)80313-2.CrossRefPubMed
73.
go back to reference Ellis CN, Krueger GG: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001, 345: 248-55. 10.1056/NEJM200107263450403.CrossRefPubMed Ellis CN, Krueger GG: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001, 345: 248-55. 10.1056/NEJM200107263450403.CrossRefPubMed
74.
go back to reference Kraan MC, van Kuijk AWR, Dinant HJ, et al: Alefacept treatment in psoriatic arthritis. Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum. 2002, 46: 2776-84. 10.1002/art.10543.CrossRefPubMed Kraan MC, van Kuijk AWR, Dinant HJ, et al: Alefacept treatment in psoriatic arthritis. Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum. 2002, 46: 2776-84. 10.1002/art.10543.CrossRefPubMed
75.
go back to reference Mease P, Gladman D, Keystone E: Efficacy of Alefacept in Combination with Methotrexate in the Treatment of Psoriatic Arthritis. Ann Rheum Dis. 2005, 64 (SIII): 324- Mease P, Gladman D, Keystone E: Efficacy of Alefacept in Combination with Methotrexate in the Treatment of Psoriatic Arthritis. Ann Rheum Dis. 2005, 64 (SIII): 324-
76.
go back to reference Gladman D, Mease P, Keystone E: Safety of Alefacept in Combination with Methotrexate in the Treatment of Psoriatic Arthritis. Ann Rheum Dis. 2005, 64 (SIII): 324-325. Gladman D, Mease P, Keystone E: Safety of Alefacept in Combination with Methotrexate in the Treatment of Psoriatic Arthritis. Ann Rheum Dis. 2005, 64 (SIII): 324-325.
77.
go back to reference Leonardi , Papp , Gordon , Menter , Feldman , Cato , Walicke , Compton , Gottlieb : Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol. 2005, 52: 425-433. 10.1016/j.jaad.2004.09.029.CrossRefPubMed Leonardi , Papp , Gordon , Menter , Feldman , Cato , Walicke , Compton , Gottlieb : Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol. 2005, 52: 425-433. 10.1016/j.jaad.2004.09.029.CrossRefPubMed
78.
go back to reference Menter , Gordon , Carey , Hamilton , Glazer , Caro , Li , Gulliver : Efficacy and Safety Observed During 24 Weeks of Efalizumab Therapy in Patients with Moderate to Severe Plaque Psoriasis. Arch Dermatol. 2005, 141: 31-38. 10.1001/archderm.141.1.31.CrossRefPubMed Menter , Gordon , Carey , Hamilton , Glazer , Caro , Li , Gulliver : Efficacy and Safety Observed During 24 Weeks of Efalizumab Therapy in Patients with Moderate to Severe Plaque Psoriasis. Arch Dermatol. 2005, 141: 31-38. 10.1001/archderm.141.1.31.CrossRefPubMed
80.
go back to reference Barker JN, Jones ML, Mitra RS, et al: Modulation of keratinocyte-derived interleukin-8 which is chemotactic for neutrophils and T lymphocytes. Am J Pathol. 1991, 139: 869-876.PubMedCentralPubMed Barker JN, Jones ML, Mitra RS, et al: Modulation of keratinocyte-derived interleukin-8 which is chemotactic for neutrophils and T lymphocytes. Am J Pathol. 1991, 139: 869-876.PubMedCentralPubMed
81.
go back to reference Singri P, West DP, Gordon KB: Patterns of cytokine production in psoriatic synovium. Arch Dermatol. 2002, 138: 657-663. 10.1001/archderm.138.5.657.PubMed Singri P, West DP, Gordon KB: Patterns of cytokine production in psoriatic synovium. Arch Dermatol. 2002, 138: 657-663. 10.1001/archderm.138.5.657.PubMed
82.
go back to reference Bresnihan B, Cunnane G: Interleukin-1 receptor antagonist. Rheum Dis Clin North Am. 1998, 24: 187-199. 10.1016/S0889-857X(05)70029-6.CrossRef Bresnihan B, Cunnane G: Interleukin-1 receptor antagonist. Rheum Dis Clin North Am. 1998, 24: 187-199. 10.1016/S0889-857X(05)70029-6.CrossRef
83.
go back to reference Ritchlin C, Haas-Smith SA, Hicks D, et al: Patterns of cytokine production in psoriatic synovium. J Rheum. 1998, 25: 1544-1552.PubMed Ritchlin C, Haas-Smith SA, Hicks D, et al: Patterns of cytokine production in psoriatic synovium. J Rheum. 1998, 25: 1544-1552.PubMed
84.
go back to reference Reich K, Garbe C, Blaschke V, et al: Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol. 2001, 116: 319-329. 10.1046/j.1523-1747.2001.01248.x.CrossRefPubMed Reich K, Garbe C, Blaschke V, et al: Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol. 2001, 116: 319-329. 10.1046/j.1523-1747.2001.01248.x.CrossRefPubMed
85.
go back to reference McInnes IB, Illei GG, Danning CL, et al: IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol. 2001, 167: 2161-2168.CrossRef McInnes IB, Illei GG, Danning CL, et al: IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol. 2001, 167: 2161-2168.CrossRef
86.
go back to reference Trepicchio WL, Ozawa M, Walter IB, et al: Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest. 1999, 104: 1527-1537.PubMedCentralCrossRefPubMed Trepicchio WL, Ozawa M, Walter IB, et al: Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest. 1999, 104: 1527-1537.PubMedCentralCrossRefPubMed
87.
go back to reference Krueger JG, Walters IB, Miyazawa M, et al: Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol. 2000, 43: 448-458. 10.1067/mjd.2000.106515.CrossRefPubMed Krueger JG, Walters IB, Miyazawa M, et al: Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol. 2000, 43: 448-458. 10.1067/mjd.2000.106515.CrossRefPubMed
88.
go back to reference Utset TO, Auger JA, Peace D, et al: Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheum. 2002, 29: 1907-1913.PubMed Utset TO, Auger JA, Peace D, et al: Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheum. 2002, 29: 1907-1913.PubMed
89.
go back to reference Abrams JR, Kelley SL, Hayes E, et al: Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-Immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med. 2000, 192: 681-693. 10.1084/jem.192.5.681.PubMedCentralCrossRefPubMed Abrams JR, Kelley SL, Hayes E, et al: Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-Immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med. 2000, 192: 681-693. 10.1084/jem.192.5.681.PubMedCentralCrossRefPubMed
90.
go back to reference Gottlieb A, Kang S, Linden K, Lebwohl M, Menter A, Abdulghani A, Goldfrab M, Cheiffo N, Tortoritis : Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin Imm. 2004, 111: 28-37. 10.1016/j.clim.2004.01.006.CrossRef Gottlieb A, Kang S, Linden K, Lebwohl M, Menter A, Abdulghani A, Goldfrab M, Cheiffo N, Tortoritis : Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin Imm. 2004, 111: 28-37. 10.1016/j.clim.2004.01.006.CrossRef
Metadata
Title
Psoriatic arthritis: Pathogenesis and novel immunomodulatory approaches to treatment
Authors
Sarah Cassell
Arthur Kavanaugh
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Journal of Immune Based Therapies and Vaccines / Issue 1/2005
Electronic ISSN: 1476-8518
DOI
https://doi.org/10.1186/1476-8518-3-6

Other articles of this Issue 1/2005

Journal of Immune Based Therapies and Vaccines 1/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.